M. Leleti

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Discovery of Potent and Selective PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, Journal of medicinal chemistry.

Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.

N. Walker, N. Sträter, D. Mandal, 2020, Journal of medicinal chemistry.

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

T. Schall, I. Charo, Daniel M. Johnson, 2016, PloS one.

Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).

N. Walker, U. Schindler, J. Powers, 2021, Journal of medicinal chemistry.

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

J. Powers, L. Seitz, Lixia Jin, 2019, Investigational New Drugs.

Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3Kγ Inhibitor

J. Powers, Guillaume Mata, A. Mailyan, 2022, Organic Process Research & Development.

Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2b Receptor Antagonist

J. Powers, Brandon R. Rosen, D. Miles, 2020 .

Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, ACS medicinal chemistry letters.

Discovery of AB680 - A Potent and Selective Inhibitor of CD73.

N. Walker, N. Sträter, Lijuan Fu, 2020, Journal of medicinal chemistry.

Improved synthesis of sterically encumbered heteroaromatic biaryls from aromatic β-keto esters

J. Powers, Brandon R. Rosen, D. Miles, 2020 .

Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression

F. Soriano, U. Schindler, J. Powers, 2019, Maintenance of Immune Balance: Effects of Targeted and Immune Therapies.

Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

F. Soriano, U. Schindler, J. Powers, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 4572: Characterization of the potent and selective A2aR antagonist AB928 for the treatment of cancer

A. Becker, J. Jaén, J. Powers, 2017 .

509 Potent and selective inhibition Of AXL receptor tyrosine kinase for the treatment of cancer

J. Powers, A. Udyavar, S. Cho, 2020, Journal for ImmunoTherapy of Cancer.

Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.

N. Walker, N. Sträter, J. Powers, 2021, Journal of medicinal chemistry.

46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma

F. Soriano, A. Mailyan, L. Seitz, 2022, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.